Therapeutic Research Areas
Focusing on therapeutic areas that impact the lives of millions worldwide
We are always seeking better ways to help people living with serious medical conditions. It’s what drives us forward and inspires us to stay the course in challenging therapeutic areas. Sunovion is fully engaged in our quest for treatment paths that will improve the lives of millions with consequential mental health disorders. At the same time, we are striving to advance the science of medicine for other high-burden areas.
There are currently two global Sunovion/Sumitomo Dainippon pharma assets in Phase III development which are being assessed for potential commercialisation in Europe.
APL-130277 which is in development for the treatment of OFF episodes associated with Parkinson’s disease. This important asset for Sunovion resulted from the acquisition of Cynapsus Therapeutics in 2016.
Dasotraline, which is being assessed for treatment in both adult and childhood ADHD, entered Phase III early in 2015.
Our focal areas by the numbers
- ~1 in 6 of the world’s population suffer from neurological disorders1
- ~50 million Europeans experience mental disorders (estimate)2
- ~5 million Europeans experience schizophrenia3
Supporting independent, quality medical research
We partner with a wide range of medical researchers, academic institutions and organisations dedicated to advancing medical science in our key therapeutic focus areas.